BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22023519)

  • 21. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
    Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
    Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion.
    Hernández-Sánchez M; Rodríguez-Vicente AE; Hernández JÁ; Lumbreras E; Sarasquete ME; Martín AÁ; Benito R; Vicente-Gutiérrez C; Robledo C; Heras Nde L; Rodríguez JN; Alcoceba M; Coca AG; Aguilar C; González M; Hernández-Rivas JM
    Leuk Res; 2016 Jul; 46():30-6. PubMed ID: 27111859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
    Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
    Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia.
    Lehmann S; Ogawa S; Raynaud SD; Sanada M; Nannya Y; Ticchioni M; Bastard C; Kawamata N; Koeffler HP
    Cancer; 2008 Mar; 112(6):1296-305. PubMed ID: 18246537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and biological relevance of genomic heterogeneity in chronic lymphocytic leukemia.
    Friedman DR; Lucas JE; Weinberg JB
    PLoS One; 2013; 8(2):e57356. PubMed ID: 23468975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
    Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
    Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
    Nabhan C; Raca G; Wang YL
    JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
    Steinbrecher D; Jebaraj BMC; Schneider C; Edelmann J; Cymbalista F; Leblond V; Delmer A; Ibach S; Tausch E; Scheffold A; Bloehdorn J; Hallek M; Dreger P; Döhner H; Stilgenbauer S
    Leuk Lymphoma; 2018 Jul; 59(7):1614-1623. PubMed ID: 29063805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia.
    Braga TV; Evangelista FCG; Gomes LC; Araújo SSDS; Carvalho MDG; Sabino AP
    Biomed Pharmacother; 2017 Aug; 92():864-869. PubMed ID: 28599250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
    Shindiapina P; Brown JR; Danilov AV
    Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia.
    Karhu R; Tobin G; Thunberg U; Vilpo L; Sundström C; Knuutila S; Rosenquist R; Vilpo J
    Genes Chromosomes Cancer; 2003 Aug; 37(4):417-20. PubMed ID: 12800154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat E; Dreger P
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in chronic lymphocytic leukemia.
    Vyas N; Hassan A
    Indian J Cancer; 2012; 49(1):137-43. PubMed ID: 22842181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations.
    Vlachonikola E; Pechlivanis N; Karakatsoulis G; Sofou E; Gkoliou G; Jeromin S; Stavroyianni N; Ranghetti P; Scarfo L; Österholm C; Mansouri L; Notopoulou S; Siorenta A; Anagnostopoulos A; Ghia P; Haferlach C; Rosenquist R; Psomopoulos F; Kouvatsi A; Baliakas P; Stamatopoulos K; Chatzidimitriou A
    Front Oncol; 2023; 13():1097942. PubMed ID: 36816924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allelotyping in B-cell chronic lymphocytic leukemia (B-CLL).
    Novak U; Tobler A; Fey MF
    Leuk Lymphoma; 2004 May; 45(5):887-96. PubMed ID: 15291345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pathogenesis of chronic lymphocytic leukemia].
    Fukuda T
    Rinsho Ketsueki; 2015 Mar; 56(3):261-8. PubMed ID: 25876778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SnapShot: Chronic Lymphocytic Leukemia.
    Ten Hacken E; Guièze R; Wu CJ
    Cancer Cell; 2017 Nov; 32(5):716-716.e1. PubMed ID: 29136511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities.
    Jimenez-Zepeda VH; Chng WJ; Schop RF; Braggio E; Leis JF; Kay N; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):467-76. PubMed ID: 23876845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.